Information sourced from BMJ:
J Neurol Neurosurg Psychiatry doi:10.1136/jnnp-2016-313458
[Free full-text J Neurol Neurosurg Psychiatry article PDF | PubMed® abstract]
Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention
Andre Leite Gonçalves, Adriana Martini Ferreira, Reinaldo Teixeira Ribeiro, et al.
Correspondence to Dr Mario Fernando Prieto Peres, Albert Einstein Hospital, R Joaquim Eugenio de Lima, 881 cj 709, São Paulo 01403-001, Brazil; email@example.com
Introduction Melatonin has been studied in headache disorders. Amitriptyline is efficacious for migraine prevention, but its unfavourable side effect profile limits its use.
Methods A randomised, double-blind, placebo-controlled study was carried out. Men and women, aged 18–65 years, with migraine with or without aura, experiencing 2–8 attacks per month, were enrolled. After a 4-week baseline phase, 196 participants were randomised to placebo, amitriptyline 25 mg or melatonin 3 mg, and 178 took a study medication and were followed for 3 months (12 weeks). The primary outcome was the number of migraine headache days per month at baseline versus last month. Secondary end points were responder rate, migraine intensity, duration and analgesic use. Tolerability was also compared between groups.
Results Mean headache frequency reduction was 2.7 migraine headache days in the melatonin group, 2.2 for amitriptyline and 1.1 for placebo. Melatonin significantly reduced headache frequency compared with placebo (p=0.009), but not [with] amitriptyline (p=0.19). Melatonin was superior to amitriptyline in the percentage of patients with a greater than 50% reduction in migraine frequency. Melatonin was better tolerated than amitriptyline. Weight loss was found in the melatonin group, a slight weight gain in placebo and significantly for amitriptyline users.
Conclusions Melatonin 3 mg is better than placebo for migraine prevention, more tolerable than amitriptyline and as effective as amitriptyline 25 mg.
Copyright © 2016 by the BMJ Publishing Group Ltd. All rights reserved.
The above message comes from BMJ, who is solely responsible for its content.
You have received this email because you requested follow-up information to an Epocrates DocAlert® message. For more information about Epocrates, please click here.
For questions, feedback, or suggestions regarding Epocrates DocAlert® messages, please contact the Medical Information Team at firstname.lastname@example.org.